SANOFI-SYNTHELABO
Halfjaarcijfers Sanofi-Synthelabo
Strong growth in consolidated sales
In the first half of 2003
+14.4% ON A COMPARABLE BASIS1
+6.1% ON A REPORTED BASIS
- Acceleration in sales growth in the second quarter on a comparable basis1 (15.4%)
- Second-quarter invoiced US sales of Plavix(r) in line with demand
- Continuing success for Eloxatin(r)
- 2003 EPS2 growth forecast confirmed
Lees verder op onze website:
http://www.sanofi-synthelabo.nl
23 jul 03 12:54